During the past decade, Korean Cancer Study Group conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Korean Cancer Study Group" are "DDR Gene Mutation" (1 trials), "Hormone Refractory Prostate Cancer" (1 trials) and "Metastatic Solid Tumor" (1 trials). Many other conditions were trialed in "Korean Cancer Study Group" in a lesser frequency.

Most popular intervention types in "Korean Cancer Study Group" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Nivolumab" (1 trials) and "TKI258" (1 trials). Other intervention names were less common.

The vast majority of trials in "Korean Cancer Study Group" are 1 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Korean Cancer Study Group". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Korean Cancer Study Group, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Korean Cancer Study Group, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".